The global heart attack diagnostics market size was USD 12.40 Bn in 2022 and is likely to reach USD 23.90 Bn by 2031, expanding at a CAGR of 7.1% during 2023–2031. The market growth is attributed to the rising prevalence of heart disease cases, increasing research & government initiatives, and increasing health expenditure.
Heart attack, also known as Myocardial Infarction (MI), is a type of heart disease that generally occurred when the heart stops its normal function of circulating blood and oxygen. Without proper medications or medical guidelines, patients with heart diseases have a high risk of heart attack or cardiac arrest which can cause death.
The pathophysiology of heart attack includes tissue necrosis of the myocardium layer of the heart. Bad diet, obesity, high cholesterol, smoking, and hypertension are some of the concerning factors that increase the probability of heart disease in 1 out of 5 people worldwide. As a result, technical improvements and diagnostic treatments are improving and developing.
The COVID-19 pandemic has moderately increased the demand for the heart attack diagnostics market. There is an estimated increase in the occurrence of heart disease due to coronavirus contact. Those prone to heart illnesses have a high probability of death if the diagnosis of the virus is delayed. Some early symptoms of COVID-19 are associated with the heart such as chest pain, fatigue, and nausea.
Heart Attack Diagnostics Market Dynamics
The global heart attack diagnostics market report has up-to-date insights that help in formulating a strategic roadmap about the estimated market scenario and performance from 2023 to 2031.
Drivers
The rising incidence of coronary artery disease (CAD) and heart stroke, the growing number of aging populaces, and inactive lifestyles need assistance. This results in increased demand for heart attack diagnostics. Increasing tobacco and & alcohol consumption, rising prevalence of obesity and high blood pressure & diabetes, and improper diet are expected to boost the market expansion during the forecast period.
Restraints
The high cost of heart attack diagnostics therapy is acting as a major expected factor to hamper the market growth in the coming years. In case of a heart attack, patients often require immediate support such as ambulance services, diagnostic tests for heart attack, and hospitalization. The costs included in these support services are often high. Cardiologist appointments, medication, and testing are estimated to be some of the expensive processes that impact restraining the market.
Opportunities
Rising research collaborations to develop advanced technology and increasing government initiatives for the development of healthcare infrastructure are projected to create lucrative opportunities for market expansion during the forecast period.
Scope of Heart Attack Diagnostics Market Report
The global heart attack diagnostics market research report includes an assessment of the market trends, market segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Heart Attack Diagnostics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2020–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Test Type (Electrocardiogram, Blood Tests [Troponin and Creatine Kinase MB Isoenzyme], Computerized Cardiac Tomography, Angiogram, and Echocardiogram) and End-user (Hospitals, Diagnostics Centers, Ambulatory Surgical Centers, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Siemens Healthcare AG; Midmark Corporation; Koninklijke Phillips N.V.; Schiller AG; Hitachi, Ltd.; F. Hoffmann-La Roche Ltd.; Abbott; Bio-Rad Laboratories, Inc.; Beckman Coulter, Inc.; and CANON MEDICAL SYSTEMS CORPORATION
|
Heart Attack Diagnostics Market Segment Insights
Based on test types, the heart attack diagnostics market is divided into electrocardiogram, blood tests, computerized cardiac tomography, angiogram, and echocardiogram. The blood test segment is further divided into troponin and creatine kinase MB isoenzyme (CK-MB).
The blood test segment is expected to expand at a significant growth rate during the projection period, as the troponin blood test is widely used for the detection of heart disease across the globe.
On the basis of end-user, the global heart attack diagnostics market is segregated into hospitals, diagnostics centers, ambulatory surgical centers, and others. The hospital segment is projected to register a considerable CAGR during the forecast period, attributed to the estimated increased number of hospitals in the regions globally.
Among the hospitals globally, US-based hospitals alone are estimated to have carried out about 8,00,000 cardiac operations. This factor is estimated to have a key share in the expansion of the market.
In terms of region, the global heart attack diagnostics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period, owing to the rising awareness and health expenditure on heart disease, desk-bound lifestyle, and adoption of advanced technology in the region.
Segments
The global heart attack diagnostics market has been segmented on the basis of
Test Type
- Electrocardiogram
- Blood Tests
- Troponin
- Creatine Kinase MB Isoenzyme
- Computerized Cardiac Tomography
- Angiogram
- Echocardiogram
End-user
- Hospitals
- Diagnostics Centers
- Ambulatory Surgical Centers
- Others
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the global heart attack diagnostic market are Siemens Healthcare AG; Midmark Corporation; Koninklijke Phillips N.V.; Schiller AG; Hitachi, Ltd.; F. Hoffmann-La Roche Ltd.; Abbott; Bio-Rad Laboratories, Inc.; Beckman Coulter, Inc.; and CANON MEDICAL SYSTEMS CORPORATION.
These companies adopted development strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production expansion to expand their consumer base worldwide. For instance,
- In April 2021, F. Hoffmann-La Roche Ltd. launched a series of five innovations for two main cardiac biomarkers using the Elecsys technology, which is a highly sensitive cardiac troponin and N-terminal pro-brain natriuretic peptide test.
- In July 2021, CANON MEDICAL SYSTEMS CORPORATION partnered with Cleerly, Inc. for the adoption of cardiac CT, which is projected to bring key advancements in the heart disease diagnostic industry.
Request For Customization
Enquiry Before Buying
Speak With Analyst
